MENU
ELVN
AS OF
Feb 4, 04:59 PM (EDT)
Price
$27.84
Change
+$0.24 (+0.87%)
Capitalization
1.64B
36 days until earnings call
Intraday BUY SELL Signals
+Compare
ELVN
Stock ticker: NASDAQ
AS OF
Feb 4, 04:59 PM (EDT)
Price
$27.84
Change
+$0.24 (+0.87%)
Capitalization
1.64B

ELVN Enliven Therapeutics Forecast, Technical & Fundamental Analysis

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics... Show more

ELVN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ELVN with price predictions
Feb 03, 2026

ELVN in upward trend: price rose above 50-day moving average on January 08, 2026

ELVN moved above its 50-day moving average on January 08, 2026 date and that indicates a change from a downward trend to an upward trend. In of 48 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 30, 2026. You may want to consider a long position or call options on ELVN as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ELVN just turned positive on February 02, 2026. Looking at past instances where ELVN's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for ELVN crossed bullishly above the 50-day moving average on January 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for ELVN moved above the 200-day moving average on January 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ELVN advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ELVN moved out of overbought territory on February 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where ELVN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELVN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ELVN broke above its upper Bollinger Band on February 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ELVN entered a downward trend on January 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.434) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (331.843).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ELVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ELVN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ELVN is expected to report earnings to rise 42.38% to -45 cents per share on March 12

Enliven Therapeutics ELVN Stock Earnings Reports
Q4'25
Est.
$-0.46
Q3'25
Beat
by $0.18
Q2'25
Beat
by $0.06
Q1'25
Missed
by $0.07
Q4'24
Beat
by $0.06
The last earnings report on November 12 showed earnings per share of -31 cents, beating the estimate of -50 cents. With 478.21K shares outstanding, the current market capitalization sits at 1.64B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
6200 Lookout Road
Phone
+1 720 647-8519
Employees
46
Web
https://www.enliventherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FPCSX44.39N/A
N/A
FPA Crescent Supra Institutional
FSUMX16.88N/A
N/A
Fidelity Series Sustainable U.S. Market
TQCIX20.48-0.03
-0.15%
Touchstone Dividend Equity Institutional
MOSAX8.71-0.05
-0.57%
MassMutual Overseas A
CWVGX25.19-0.42
-1.64%
Calvert International Equity A

ELVN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with SYRE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVN
1D Price
Change %
ELVN100%
-2.02%
SYRE - ELVN
53%
Loosely correlated
+1.65%
XNCR - ELVN
51%
Loosely correlated
-0.99%
BHVN - ELVN
48%
Loosely correlated
-3.06%
APGE - ELVN
48%
Loosely correlated
+4.97%
ZYME - ELVN
48%
Loosely correlated
+1.17%
More